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A B S T R A C T
Background
Bronchiectasis is increasingly recognized as a major cause of respiratory morbidity especially in developing countries. Even in affluent
countries, bronchiectasis is increasingly seen in some community subsections (e.g. Aboriginal communities) and occurs as a comorbidity
and disease modifier in respiratory diseases such as chronic obstructive pulmonary disease (COPD). Respiratory exacerbations in people
with bronchiectasis are associated with reduced quality of life, accelerated pulmonary decline, hospitalisation and even death. Conjugate
pneumococcal vaccine is part of the routine infant immunisation schedule in many countries. Current recommendations for additional
pneumococcal vaccination include children and adults with chronic suppurative disease.
Objectives
To evaluate the effectiveness of pneumococcal vaccine as routine management in children and adults with bronchiectasis in (a) reducing
the severity and frequency of respiratory exacerbations and (b) pulmonary decline.
Search strategy
TheCochrane Register of Controlled Trials (CENTRAL), theCochrane Airways Group Specialised Register,MEDLINE and EMBASE
databases were searched by the Cochrane Airways Group. Pharmaceutical manufacturers of pneumococcal vaccines were also contacted.
The latest searches were performed in November 2007.
Selection criteria
All randomised controlled trials that utilised pneumococcal vaccine on children and adultswith bronchiectasis. All types of pneumococcal
vaccines were included.
Data collection and analysis
Results of searches were reviewed against pre-determined criteria for inclusion. No eligible trials were identified and thus no data was
available for analysis. One small non-randomised controlled trial in children was reported.
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Main results
No randomised controlled trials pertaining effectiveness of pneumococcal vaccine as routine management in children and adults with
bronchiectasis were found. A benefit in elimination of Strep. pneumoniae in the sputum was found in a non-randomised trial in
children but no clinical effect was described.
Authors’ conclusions
At present, there is a lack of reliable evidence to support or refute the routine use of pneumococcal vaccine as routine management in
children and adults with bronchiectasis. Randomised controlled trials examining the efficacy of this intervention using various vaccine
types in different age groups are needed. Until further evidence is available, it is recommended that health providers adhere to national
guidelines.
P L A I N L A N G U A G E S U M M A R Y
Pneumococcal vaccines for children and adults with bronchiectasis
Inmany countries vaccination for the protection against infection of the bacteria pneumococcus, is part of the immunisation schedule for
infants as well as, for people with bronchiectasis. In this review, our search for randomised control trials that examined the effectiveness
of pneumococcal vaccines for people with bronchiectasis revealed no relevant studies. We thus cannot draw any conclusions for, or
against, the routine pneumococcal vaccinations in people with bronchiectasis. However, we would recommend that national guidelines
be followed until further evidence is available.
B A C K G R O U N D
Bronchiectasis, previously termed an ’orphan’s disease’ is increas-
ingly recognized as a major cause of respiratory morbidity espe-
cially in developing countries (Karadag 2005) and in pockets of
affluent countries (Edwards 2003, Singleton 2000). Of diverse
aetiology, bronchiectasis is often a result of repeated respiratory
infections or may be due to rare immune deficiencies. Increas-
ingly recognised as a common final pathway for a variety of dis-
eases, it is seen to complicate both common and uncommon res-
piratory illnesses such as COPD, bronchiolitis obliterans and sar-
coidosis (Patel 2004, Chang 1998, Lewis 2002) and also sec-
ondary pulmonary illnesses such as autoimmune diseases. Its co-
existence increases the morbidity and mortality of the underlying
disease (Patel 2004, Lewis 2002, Keistinen 1997). For instance,
bronchiectasis is reported to occur in 29-50% of COPD (Patel
2004, O’Brien 2000) and when present, increases the severity and
frequency of respiratory exacerbations (Patel 2004, Gursel 2006).
Thus, management of the symptoms and prevention of progres-
sion of bronchiectasis is important.
The dominant symptoms and signs of bronchiectasis are a pro-
ductive or wet cough, dyspnoea on exertion and presence of other
respiratory signs (clubbing, chest wall deformity, respiratory noises
such as wheeze or crepitations on auscultation). In the long term,
pulmonary declinemay occur (Keistinen 1997, Twiss 2006). Chil-
dren and adults with bronchiectasis suffer from recurrent acute
exacerbations, some necessitating inpatient care. Effective man-
agement regimes for bronchiectasis should improve quality of life,
reduce the frequency and severity of respiratory exacerbations and
rate of pulmonary decline. Cole’s ’vicious circle hypothesis’ sug-
gestsmicrobial colonizationor infection as a key factor in its patho-
physiology as this often leads to bronchial obstruction and a nor-
mal or exaggerated inflammatory response (Cole 1986). Treatment
modalities that prevent or limit respiratory infections should thus,
prevent or reduce respiratory decline. Respiratory infection alone
increases morbidity and reduces the quality of life in those with
bronchiectasis (Martinez-Garcia 2005). Pneumococcal respiratory
infections is a common respiratory pathogen in acute (Lucero
2004) and chronic respiratory diseases (Devitt 1977). Prevention
of pneumococcal infections through the use of pneumococcal vac-
cine should in turn, be a useful routine management modality for
children and adults with bronchiectasis. Indeed 5-yearly pneumo-
coccal vaccination is recommended for patients with bronchiecta-
sis (Chang 2002).
Pneumococcal vaccines are available in two major types; the older
pneumococcal polysaccharide vaccine and the more recent pneu-
mococcal conjugate vaccine. The 23-valent polysaccharide vac-
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cine (PPV23) contains polysaccharide antigen from 23 serotypes
and vaccine efficacy against invasive disease is estimated at 38-
53% (Conaty 2004). Although clinical trials in younger adults
have generally shown efficacy against pneumococcal pneumonia
and, or bacteraemia, the trial evidence in the elderly is less robust
(Honkanen 1999). Effectiveness in case-control studies generally
range from 56-81% except Forrester et al who demonstrated no
effectiveness (Forrester 1987). The PPV23 vaccine is relatively in-
effective in young children aged under 2 years (Lee 2003). The
heptavalent pneumococcal conjugated vaccine (PCV7) is directed
against seven serotypes and recommended for use in children less
than 5 years of age (McEllistrem 2005). Universal childhood vac-
cination in the United States has resulted in 70% decrease in in-
vasive pneumococcal disease (IPD) in children <2 years and indi-
rectly, contributed to prevention of adult IPD (Lexau 2005). The
possibility of replacement serotype disease mandates continued
data surveillance (McEllistrem 2005). Vaccines also incur cost and
can result in adverse reactions, mostly occurring as local pain and
swelling (Walker 2005, Jackson 2006). A review on the efficacy of
pneumococcal vaccines for bronchiectasis will help guide clinical
practice.
Efficacy of pneumococcal vaccines for other chronic respira-
tory diseases (Sheikh 2002, Granger 2006) and otitis media
(Straetemans 2004) are covered in other Cochrane reviews. This
systematic review will evaluate the evidence of efficacy of pneu-
mococcal vaccination in children and adults with bronchiectasis.
O B J E C T I V E S
To evaluate the effectiveness of pneumococcal vaccine as routine
management in children and adults with bronchiectasis in (a) re-
ducing the severity and frequency of respiratory exacerbations and
(b) pulmonary decline.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials using pneumococcal vaccine in
patients with bronchiectasis.
Types of participants
Adults or children with bronchiectasis (defined clinically or radi-
ologically).
Exclusion criteria: Participants with other diseases where
bronchiectasis is not present.
Types of interventions
All randomised controlled trials that utilised pneumococcal vac-
cine on children and adults with bronchiectasis. All types of pneu-
mococcal vaccines were included.
Types of outcome measures
Attempts were made to obtain data on at least one of the following
outcome measures:
(A) for short term effectiveness (12 months or less)
a) proportions of participants who had respiratory exacerbations
b) proportions of participants who were hospitalised,
c) total numbers of days with respiratory symptoms
d) total number of hospitalised days
e) mean difference in bronchiectasis severity control (QOL, cough
diary, Likert scale, visual analogue scale, level of interference of
cough, cough diary, etc),
f ) proportions experiencing adverse effects of the intervention,
(e.g. local reaction, exacerbation immediately post vaccination,
systemic effects (myalgia, fever, fatigue), etc)
Outcomes (a) to (e) will be examined globally as well as also specif-
ically to proven pneumococcal infections (from airway specimens
or rising titres)
(B) for medium to long term outcomes (more than 1 year)
g) radiology scores (high resolution computed tomography scans
or chest radiograph)
h) lung function
i) bronchiectasis severity control (QOL, cough diary, Likert scale,
visual analogue scale, level of interference of cough, cough diary,
etc),
j) relevant airway markers of inflammation.
k) other non-respiratory outcomes (otitis media, bacteraemia,
meningitis, etc) caused by pneumococcus.
Search methods for identification of studies
The following topic search strategy was used to identify relevant
randomised controlled trials from electronic databases:
(“bronchiectasis” OR “suppurative lung disease”) AND ((vaccin*
OR immunis*) AND (pneum*)) (all as textword or index terms).
For the full strategies see Table 1
Trials were identified from the following sources:
1. The Cochrane Airways Group Specialised Trials Register
2. The Cochrane Central Register of Controlled Trials (CEN-
TRAL)
3. MEDLINE (1966 to Nov 2007). Topic search strategy com-
bined with the RCT search filter as outlined in the Airways Group
module.
4. OLDMEDLINE (1950 to 1965). Topic search strategy com-
bined with the RCT search filter as outlined in the Airways Group
module.
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5. EMBASE (1980 to Nov 2007).Topic search strategy combined
with the RCT search filter as outlined in the Airways Group mod-
ule.
6. The list of references in relevant publications.
7. Written communication with the authors of trials would have
been included in the review if necessary.
7. Pharmaceutical companies that manufacture pneumococcal
vaccines.
Data collection and analysis
Retrieval of studies: From the title, abstract, or descriptors, two
reviewers (CC, AC) independently reviewed literature searches to
identify potentially relevant trials for full review. Searches of bibli-
ographies and texts were conducted to identify additional studies.
From the full text using specific criteria, the same two reviewers
independently selected trials for inclusion. Agreement would have
been measured using kappa statistics. Disagreement would have
been resolved by adjudication (RS and PM).
It was planned that trials that satisfied the inclusion criteria would
have been reviewed and the following information recorded: study
setting, year of study, source of funding, patient recruitment de-
tails (including number of eligible subjects), inclusion and exclu-
sion criteria, other symptoms, randomisation and allocation con-
cealment method, numbers of participants randomised, blinding
(masking) of participants, care providers and outcome assessors,
dose and type of intervention, duration of therapy, co-interven-
tions, numbers of patients not followedup, reasons forwithdrawals
from study protocol (clinical, side-effects, refusal and other), de-
tails on side-effects of therapy, andwhether intention-to-treat anal-
yses were possible. Data would have been extracted on the out-
comes described previously. Further information would have been
requested from the authors when required.
Studies included in the review would have undergone quality as-
sessment performed independently by 2 reviewers. Four compo-
nents of quality would have been assessed:
1. Allocation concealment. Trialswould have been scored as:Grade
A: Adequate concealment, Grade B: Unclear, Grade C: Clearly
inadequate concealment. (Grade A = high quality).
2. Blinding. Trials would have been scored as: Grade A: Participant
and care provider and outcome assessor blinded, Grade B: Out-
come assessor blinded, Grade C: Unclear, Grade D: No blinding
of outcome assessor (Grade A, B = high quality).
3. Reporting of participants by allocated group. Trials would have
been scored as: Grade A: The progress of all randomised children
in each group described, Grade B: Unclear or no mention of with-
drawals or dropouts, GradeC: The progress of all randomised chil-
dren in each group clearly not described. (Grade A = high quality).
4. Follow-up. Trials would have been scored as: Grade A: Out-
comes measured in >90% (where withdrawals due to complica-
tions and side-effects are categorised as treatment failures), Grade
B: Outcomes measured in 80-90%, Grade C: Unclear, Grade D:
Outcomes measured in <80%. (Grade A = high quality).
While only the allocation concealment quality assessment would
have been displayed in the meta-analysis figures, all assessments
would have been included in the “Characteristics of included stud-
ies” table. Inter-reviewer reliability for the identification of high
quality studies for each component would have been measured by
the Kappa statistic.
STATISTICS
It was planned that the results from studies that met the inclusion
criteria and reported any of the outcomes of interest would have
been included in the subsequent meta-analyses. The summary
weighted odds ratio and 95% confidence interval (fixed effects
model) would have been calculated (Cochrane statistical package,
RevMan version 4.2). For cross-over studies, mean treatment dif-
ferences would have been calculated from raw data, extracted or
imputed and entered as fixed effects generic inverse variance (GIV)
outcome, to provide summary weighted differences and 95% con-
fidence intervals. Numbers needed to treat (NNT) would have
been calculated from the pooled OR and its 95% CI applied to
a specified baseline risk using an online calculator (Cates 2003).
If studies reported outcomes using different measurement scales,
the standardised mean difference would have been estimated. Any
heterogeneity between the study results would have been described
and tested to see if it reached statistical significance using a chi-
squared test. The 95% confidence interval estimated using a ran-
dom effects model would have been included whenever there are
concerns about statistical heterogeneity.
SUB-GROUP ANALYSIS:
The following a priori sub-group analyses was planned:
1. children (aged 18 years or less) and adults (>18 years)
2. types of pneumococcal vaccine
3. type of control group
4. participant type (bronchiectasis as primary disease vs bronchiec-
tasis as co-existent disease)
5. severity of bronchiectasis (based on lung function)
Sensitivity analyses were also planned to assess the impact of the
potentially important factors on the overall outcomes:
a) study quality;
b) variation in the inclusion criteria;
c) differences in the medications used in the intervention and
comparison groups;
d) differences in outcome measures;
e) analysis using random effects model;
f ) analysis by “treatment received”; and
g) analysis by “intention-to-treat”.
R E S U L T S
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Description of studies
See: Characteristics of excluded studies.
The searches identified 3 potentially relevant publications but
none fulfilled the study eligibility criteria (see Table of excluded
studies).
Risk of bias in included studies
Not applicable as there were no eligible studies.
Effects of interventions
The Airways Group specialised register/search identified 44 po-
tentially relevant titles. After assessing the abstracts, 3 publications
were considered for inclusion into review including one non-En-
glish article (Russian). No additional studies were found in the
review articles. No additional data were available from the two
pharmaceutical companies contacted (Merck Sharp&Dohme and
Wyeth inAustralia). The only study in patients with bronchiectasis
where a comparative group was used, was a non-randomised study
in Russian (Ryzhov 2005). In this study (Ryzhov 2005) in chil-
dren with chronic lung disease (including bronchiectasis), 25 were
vaccinated with PPV23, 13 with Haemophilus influenzae vaccine
and 40 children were not vaccinated. The authors described that,
a year after vaccination with PPV23, S. pneumoniae were isolated
in monoculture in 3 out of 25 cases (88% elimination) (Ryzhov
2005). An update search run in November 2007 did not identify
any additional studies.
D I S C U S S I O N
No randomised controlled trials comparing the effectiveness of
pneumococcal vaccine as routine management in children and
adults with bronchiectasis were identified.
In the target group examined in this Cochrane review, the one
controlled study identified was not randomised (Ryzhov 2005);
this study described efficacy with respect to microbiology of the
sputum but clinical evaluation was not examined.
Large trials andmeta-analysis have demonstrated that pneumococ-
cal vaccination protects children and adults from invasive pneu-
mococcal disease (de Roux 2005), thus many recommendations
exist for regular pneumococcal vaccination for those at risk (in-
cluding patients with suppurative lung disease). This Cochrane
review however illustrates the glaring lack of evidence to support
or refute these recommendations in the target group of people
with bronchiectasis. Whilst we cannot always “wait for perfect
data”, others have cautioned against “availability creep” with re-
spect to the gap between policy and evidence (Jefferson 2006).
Until RCTs are undertaken to examine the question, we cannot
be confident whether routine pneumococcal vaccination in chil-
dren and adults with bronchiectasis is beneficial. The feasibility
of performing RCTs in this target group is in question. For now,
as children and adults with bronchiectasis are at increased risk for
pneumonia and pneumococcal disease and there is some evidence
that pneumococcal vaccine can reduce pneumonia and invasive
pneumococcal disease (Lucero 2004), it would be prudent that
providers follow guidelines from the national bodies such as Advi-
sory Committee on Immunization Practices (in USA) (ACIP) and
NIPS (Australia) (NIPS) regarding recommendations for pneu-
mococcal vaccination of persons with bronchiectasis.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is a lack of evidence for or against, routine additional pneu-
mococcal vaccination for children and adults with bronchiectasis
specifically. Circumstantial data suggests that pneumococcal vac-
cination is beneficial. As children and adults with bronchiectasis
are at increased risk for pneumonia and pneumococcal disease and
there is evidence that pneumococcal vaccine can reduce pneumo-
nia and invasive pneumococcal disease, it would be prudent that
providers follow national guidelines regarding recommendations
for pneumococcal vaccination of persons with bronchiectasis. In-
dividual risk factors for adverse events should be taken into ac-
count.
Implications for research
Randomised controlled trials to establish the efficacy of pneumo-
coccal vaccination in reducing severity and frequency of respira-
tory exacerbations and pulmonary decline
in people with bronchiectasis are needed. As vaccine response al-
ters with age, age-based cohorts should include young children
(less than 2 years), children, adults and older adults. Various vac-
cine types and microbiological surveillance for possible serotype
replacement should also be examined in these RCTs. However the
difficulty in performing a RCT in the target group is acknowl-
edged.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ryzhov 2005 Non RCT. This study in Russian was a comparative study in 40 controls (unvaccinated ) and 25 children with
chronic lung disease (including bronchiectasis) using Pneumovax 23. Hib vaccination was examined in another
group
van Kessel 2005 Non RCT. Study examined antibody response to polysaccharide pneumococcal vaccine in 26 patients with
bronchiectasis of unknown aetiology
Vendrell 2005 Non RCT. Study examined antibody response to a pneumococcal unconjugate vaccine and an Haemophilus
influenzae type b conjugate vaccine in all consecutive adult patients with bronchiectasis of unknown etiology
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Search Strategies
Database Search keywords
AIRWAYS REGISTER (“bronchiectasis” OR “suppurative lung disease”) AND ((vaccin*
OR immunis*) AND (pneum*))
(all as textword or index terms)
CENTRAL #1 MeSH descriptor Bronchiectasis explode all trees
#2 bronchiect*
#3 suppurativ* near lung*
#4 MeSH descriptor Ciliary Motility Disorders explode all trees
#5 ciliary near dyskinesia
#6 kartagener*
#7 (#1 OR #2 OR #3 OR #4 OR #5 OR #6)
#8 MeSH descriptor Pneumococcal Infections explode all trees
#9 pneum*
#10 MeSH descriptor Immunization explode all trees
#11 MeSH descriptor Vaccines explode all trees
#12 immuni*
#13 vaccinat*
#14 (#8 OR #9)
#15 (#10 OR #11 OR #12 OR #13)
#16 (#14 AND #15)
#17(#16 AND #7)
MEDLINE (1966 to present) and OLDMEDLINE (1950 to 65)
(Combined with RCT filter)
1. exp Bronchiectasis/
2. bronchiect$.mp.
3. (bronch$ adj5 dilat$).mp.
4. (suppurativ$ adj5 lung$).mp.
5. (ciliary adj3 dyskinesia).mp.
6. kartagener$.mp.
7. or/1-6
8. exp Pneumococcal Infections/
9. pneum$.mp.
10. exp Immunization/
11. exp Vaccines/
12. vaccinat$.mp.
13. immuni$.mp.
14. (or/8-9) and (or/10-13)
15. (pneumoc$ adj5 vaccin$).mp.
16. (pneumoc$ adj5 immuni$).mp.
17. pneumococcal vaccines/
18. or/14-17
19. 18 and 7
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Table 1. Search Strategies (Continued)
EMBASE (1980 to 2006 Week 41)
(Combined with RCT filter)
1. exp Bronchiectasis/
2. bronchiect$.mp.
3. (bronch$ adj5 dilat$).mp.
4. (suppurativ$ adj5 lung$).mp.
5. (ciliary adj3 dyskinesia).mp.
6. kartagener$.mp.
7. or/1-6
8. exp Pneumococcal Infections/
9. pneum$.mp.
10. exp Immunization/
11. exp Vaccines/
12. vaccinat$.mp.
13. immuni$.mp.
14. (or/8-9) and (or/10-13)
15. (pneumoc$ adj5 vaccin$).mp.
16. (pneumoc$ adj5 immuni$).mp.
17. pneumococcal vaccines/
18. or/14-17
19. 18 and 7
WH A T ’ S N E W
Last assessed as up-to-date: 19 November 2007.
Date Event Description
16 April 2008 Amended Converted to new review format.
H I S T O R Y
Protocol first published: Issue 1, 2007
Review first published: Issue 2, 2007
Date Event Description
10 December 2006 New citation required and conclusions have changed Substantive amendment
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C O N T R I B U T I O N S O F A U T H O R S
For the protocol: Protocol was written by both CC and AC. RS reviewed the protocol. For the review: CC and AC selected articles
from search, extracted data and wrote the review. RS and PM contributed to writing the review and would have been adjudicators if
disagreements had occurred.
D E C L A R A T I O N S O F I N T E R E S T
None declared.
S O U R C E S O F S U P P O R T
Internal sources
• Royal Children’s Hospital Foundation, Brisbane, Australia.
External sources
• National Health and Medical Research Council, Australia.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Bronchiectasis [∗complications]; Pneumococcal Infections [∗prevention & control]; Pneumococcal Vaccines [∗therapeutic use]
MeSH check words
Adult; Child; Humans
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